JP2005520818A - Hmg−coaレダクターゼ阻害性メバロン酸誘導体の製造方法 - Google Patents
Hmg−coaレダクターゼ阻害性メバロン酸誘導体の製造方法 Download PDFInfo
- Publication number
- JP2005520818A JP2005520818A JP2003569624A JP2003569624A JP2005520818A JP 2005520818 A JP2005520818 A JP 2005520818A JP 2003569624 A JP2003569624 A JP 2003569624A JP 2003569624 A JP2003569624 A JP 2003569624A JP 2005520818 A JP2005520818 A JP 2005520818A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- iid
- phenyl
- compound
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title description 10
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical class OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 title description 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 title description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 title description 2
- 230000002401 inhibitory effect Effects 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 69
- 150000003839 salts Chemical class 0.000 claims abstract description 29
- 150000002596 lactones Chemical class 0.000 claims abstract description 16
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 9
- -1 4-chloro-4-phenoxy - phenyl Chemical group 0.000 claims description 66
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- 239000000460 chlorine Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 12
- 125000001931 aliphatic group Chemical group 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000004793 Polystyrene Substances 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 229920002223 polystyrene Polymers 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 239000003638 chemical reducing agent Substances 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 239000000741 silica gel Substances 0.000 claims description 5
- 229910002027 silica gel Inorganic materials 0.000 claims description 5
- 125000003944 tolyl group Chemical group 0.000 claims description 5
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
- 125000004423 acyloxy group Chemical group 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 229910052707 ruthenium Inorganic materials 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims description 3
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 229910052741 iridium Inorganic materials 0.000 claims description 3
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 3
- 125000005561 phenanthryl group Chemical group 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 229910052703 rhodium Inorganic materials 0.000 claims description 3
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000002676 chrysenyl group Chemical group C1(=CC=CC=2C3=CC=C4C=CC=CC4=C3C=CC12)* 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- AJUXDFHPVZQOGF-UHFFFAOYSA-N n,n-dimethyl-1-naphthylamine Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1 AJUXDFHPVZQOGF-UHFFFAOYSA-N 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 44
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 29
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 28
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 26
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- 239000000203 mixture Substances 0.000 description 19
- 239000002904 solvent Substances 0.000 description 19
- 239000003054 catalyst Substances 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000002585 base Substances 0.000 description 11
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 239000012442 inert solvent Substances 0.000 description 10
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 10
- 229960002797 pitavastatin Drugs 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 9
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 9
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 8
- 238000009835 boiling Methods 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 239000000284 extract Substances 0.000 description 7
- 238000005984 hydrogenation reaction Methods 0.000 description 7
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 7
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229960003765 fluvastatin Drugs 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- 239000000852 hydrogen donor Substances 0.000 description 6
- 150000002009 diols Chemical class 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 150000004678 hydrides Chemical class 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- OZDAOKMCMCEUHP-IBUXMESJSA-N tert-butyl (e,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-5-hydroxy-3-oxohept-6-enoate Chemical compound CC(C)(C)OC(=O)CC(=O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 OZDAOKMCMCEUHP-IBUXMESJSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 4
- 238000009901 transfer hydrogenation reaction Methods 0.000 description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 3
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 3
- 0 CC[C@]1*C*CC1 Chemical compound CC[C@]1*C*CC1 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 229960005370 atorvastatin Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 229930007927 cymene Natural products 0.000 description 3
- FESAXEDIWWXCNG-UHFFFAOYSA-N diethyl(methoxy)borane Chemical compound CCB(CC)OC FESAXEDIWWXCNG-UHFFFAOYSA-N 0.000 description 3
- 229940043279 diisopropylamine Drugs 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- IZZWJPQHPPRVLP-UHFFFAOYSA-N hexane;2-methoxy-2-methylpropane Chemical compound CCCCCC.COC(C)(C)C IZZWJPQHPPRVLP-UHFFFAOYSA-N 0.000 description 3
- 239000011261 inert gas Substances 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 description 3
- 229960000672 rosuvastatin Drugs 0.000 description 3
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 3
- 229960002855 simvastatin Drugs 0.000 description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- VXDRHGNOZCFIHZ-UHFFFAOYSA-M (4-ethoxy-3,4-dioxobutyl)-triphenylphosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCC(=O)C(=O)OCC)C1=CC=CC=C1 VXDRHGNOZCFIHZ-UHFFFAOYSA-M 0.000 description 2
- WWRCMNKATXZARA-UHFFFAOYSA-N 1-Isopropyl-2-methylbenzene Chemical compound CC(C)C1=CC=CC=C1C WWRCMNKATXZARA-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 2
- 229960005110 cerivastatin Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- YIXPTDPSXSUMRZ-BUHFOSPRSA-N ethyl (e)-5-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3-hydroxypent-4-enoate Chemical compound CCOC(=O)CC(O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 YIXPTDPSXSUMRZ-BUHFOSPRSA-N 0.000 description 2
- SZQMPNZYYHBKQS-BUHFOSPRSA-N ethyl (e)-5-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3-oxopent-4-enoate Chemical compound C12=CC=CC=C2N(C(C)C)C(/C=C/C(=O)CC(=O)OCC)=C1C1=CC=C(F)C=C1 SZQMPNZYYHBKQS-BUHFOSPRSA-N 0.000 description 2
- UHKATWVCCRPJCX-JKIKYLSZSA-N ethyl (e,3s)-5-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3-hydroxypent-4-enoate Chemical compound C12=CC=CC=C2N(C(C)C)C(/C=C/[C@@H](O)CC(=O)OCC)=C1C1=CC=C(F)C=C1 UHKATWVCCRPJCX-JKIKYLSZSA-N 0.000 description 2
- YIXPTDPSXSUMRZ-UHFFFAOYSA-N ethyl 5-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3-hydroxypent-4-enoate Chemical compound CCOC(=O)CC(O)C=CC1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 YIXPTDPSXSUMRZ-UHFFFAOYSA-N 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 2
- 229940074439 potassium sodium tartrate Drugs 0.000 description 2
- 229960002965 pravastatin Drugs 0.000 description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000001725 pyrenyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- RCARMBIYAHBUHR-UQECUQMJSA-N tert-butyl (e,3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)(C)OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RCARMBIYAHBUHR-UQECUQMJSA-N 0.000 description 2
- USGKHYXJISAYPE-PPXNOBOXSA-N tert-butyl (e,3s,5s)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoate Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@H](O)CC(=O)OC(C)(C)C)=C1C1=CC=C(F)C=C1 USGKHYXJISAYPE-PPXNOBOXSA-N 0.000 description 2
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- WKPZUCBZSGJGMI-CUVMAEJSSA-N (e,3s,5r)-1-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]hept-1-ene-3,5-diol Chemical compound CC[C@@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 WKPZUCBZSGJGMI-CUVMAEJSSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- KBMDBLCFKPRPOC-UHFFFAOYSA-N 2-bromo-3,3,3-trifluoro-2-(trifluoromethyl)propanenitrile Chemical compound FC(F)(F)C(Br)(C#N)C(F)(F)F KBMDBLCFKPRPOC-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- JAHBIRPTCXOGLB-UHFFFAOYSA-N 2-cyclopropyl-4-(4-fluorophenyl)quinoline-3-carbaldehyde Chemical compound C1=CC(F)=CC=C1C1=C(C=O)C(C2CC2)=NC2=CC=CC=C12 JAHBIRPTCXOGLB-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- MMTXSCWTVRMIIY-UHFFFAOYSA-N 3,5-dihydroxyhept-6-enoic acid Chemical group OC(=O)CC(O)CC(O)C=C MMTXSCWTVRMIIY-UHFFFAOYSA-N 0.000 description 1
- PDBMVYIMAMQDCW-UHFFFAOYSA-N 3,5-dihydroxyheptanoic acid Chemical class CCC(O)CC(O)CC(O)=O PDBMVYIMAMQDCW-UHFFFAOYSA-N 0.000 description 1
- NPWWALYZZIFFPB-UHFFFAOYSA-N 3-(4-fluorophenyl)-1-propan-2-ylindole-2-carbaldehyde Chemical compound C12=CC=CC=C2N(C(C)C)C(C=O)=C1C1=CC=C(F)C=C1 NPWWALYZZIFFPB-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 229910003849 O-Si Inorganic materials 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910003872 O—Si Inorganic materials 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- VDCSGNNYCFPWFK-UHFFFAOYSA-N diphenylsilane Chemical compound C=1C=CC=CC=1[SiH2]C1=CC=CC=C1 VDCSGNNYCFPWFK-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- BRZOIPXQRNMHSG-BUHFOSPRSA-N ethyl (e)-5-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3-oxopent-4-enoate Chemical compound CCOC(=O)CC(=O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 BRZOIPXQRNMHSG-BUHFOSPRSA-N 0.000 description 1
- QYXSFVCJCUXGJH-UHFFFAOYSA-N ethyl 3-oxo-4-(triphenyl-$l^{5}-phosphanylidene)butanoate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)CC(=O)OCC)C1=CC=CC=C1 QYXSFVCJCUXGJH-UHFFFAOYSA-N 0.000 description 1
- OHLRLMWUFVDREV-UHFFFAOYSA-N ethyl 4-chloro-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)CCl OHLRLMWUFVDREV-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005446 heptyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- YUWFEBAXEOLKSG-UHFFFAOYSA-N hexamethylbenzene Chemical compound CC1=C(C)C(C)=C(C)C(C)=C1C YUWFEBAXEOLKSG-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- UWNADWZGEHDQAB-UHFFFAOYSA-N i-Pr2C2H4i-Pr2 Natural products CC(C)CCC(C)C UWNADWZGEHDQAB-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000002608 ionic liquid Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005394 methallyl group Chemical group 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical group [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- NUMQCACRALPSHD-UHFFFAOYSA-N tert-Butyl ethyl ether Natural products CCOC(C)(C)C NUMQCACRALPSHD-UHFFFAOYSA-N 0.000 description 1
- USGKHYXJISAYPE-UQECUQMJSA-N tert-butyl (e,3r,5s)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoate Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(=O)OC(C)(C)C)=C1C1=CC=C(F)C=C1 USGKHYXJISAYPE-UQECUQMJSA-N 0.000 description 1
- RCARMBIYAHBUHR-PPXNOBOXSA-N tert-butyl (e,3s,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)(C)OC(=O)C[C@@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RCARMBIYAHBUHR-PPXNOBOXSA-N 0.000 description 1
- CHEYRYWZYKYUHU-IBUXMESJSA-N tert-butyl (e,5s)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-5-hydroxy-3-oxohept-6-enoate Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)CC(=O)CC(=O)OC(C)(C)C)=C1C1=CC=C(F)C=C1 CHEYRYWZYKYUHU-IBUXMESJSA-N 0.000 description 1
- VLGMZQAIQUOQSH-UHFFFAOYSA-N tert-butyl 3-oxohept-6-enoate Chemical compound CC(C)(C)OC(=O)CC(=O)CCC=C VLGMZQAIQUOQSH-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- AVCVDUDESCZFHJ-UHFFFAOYSA-N triphenylphosphane;hydrochloride Chemical compound [Cl-].C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 AVCVDUDESCZFHJ-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/535—Organo-phosphoranes
- C07F9/5352—Phosphoranes containing the structure P=C-
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/26—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0033—Iridium compounds
- C07F15/004—Iridium compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0046—Ruthenium compounds
- C07F15/0053—Ruthenium compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0073—Rhodium compounds
- C07F15/008—Rhodium compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
- C07F15/025—Iron compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/04—Nickel compounds
- C07F15/045—Nickel compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/06—Cobalt compounds
- C07F15/065—Cobalt compounds without a metal-carbon linkage
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Quinoline Compounds (AREA)
- Indole Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
で示される対応するラクトン部分構造を形成することもある。]、または
を含んでなる。
部分
Rは環状残基を表す。〕
で示されるHMG−CoAレダクターゼ阻害性メバロン酸誘導体またはその塩、とりわけ塩基との医薬上許容されるその塩またはそのラクトンの製造方法に関する。
〔式中、部分
で示される化合物またはその塩、またはそのラクトンの製造法であって、本発明にしたがって、
(a)式(II a)
〔式中、R1、R2およびR3は、互いに独立して、非置換またはC1−C7アルキル、ヒドロキシ、C1−C7アルコキシ、C2−C8アルカノイル−オキシ、ハロゲン、ニトロ、シアノ、およびCF3からなる群から選択される1もしくはそれ以上の置換基により置換されたフェニルを表し、そしてR4は脂肪族、環状脂肪族、芳香脂肪族または芳香族残基である。〕
で示される化合物を、式
R−CH(=O)(II b)
〔式中、Rは環状残基を示す。〕
で示される化合物と反応させること;および
(b)得られる式(II c)
で示される化合物を、式(II d)、(II d')、(II d'')、(II d''')、(II d'''')、(II d''''')、(II d'''''')、および(II d''''''')
〔式中、
MはRu、Rh、Ir、Fe、CoまたはNiであり;
L1は水素であり;
L2はアリールまたはアリール−脂肪族残基を表し;
Halはハロゲンであり;
R5は脂肪族、環状脂肪族、環状脂肪族−脂肪族、アリールまたはアリール−脂肪族残基であり、これらは、それぞれの場合において、ポリマーと結合していてもよく;
R6およびR7は、それぞれ独立して、脂肪族、環状脂肪族、環状脂肪族−脂肪族、アリールまたはアリール−脂肪族残基であり;
R8およびR9は、ぞれぞれ、フェニルであるか、またはR8およびR9はそれらが結合している炭素原子と一体となって、シクロヘキサンまたはシクロペンタン環を形成し;そして
R15はH、ハロゲン、アミノ、ニトロまたはC1−C7アルコキシであり;
式(IId)、(IId')、(IId'')、(IId''')、(IId'''')、(IId''''')、(IId'''''')または(IID''''''')で示される化合物の任意の芳香族残基は非置換であるかまたは置換されており;
式(IId'')、(IId''')、(IId'''')、(IId''''')、(IId'''''')または(IID''''''')の化合物に関して、また、(R)−または(S)−BINAPとの組合せも可能である。〕
で示される化合物からなる群から選択される還元剤の存在下で還元すること;および
(c)得られる式(II e)
〔式中、RおよびR4は上で定義した意味を有する。〕
で示される化合物を、式(II f)
〔式中、R16は脂肪族残基を表す。〕
で示される化合物と縮合すること、および
(d)得られる式(II g)
〔式中、RおよびR16は上で定義した意味を有する。〕
で示される化合物を還元すること、および
(e)得られる式(II h)
で示される化合物を加水分解すること、および
(f)得られる式(I)の化合物またはその塩を単離すること;
および、所望により、得られる式(I)の遊離酸をその塩または、それぞれ、式(I a)もしくは(I b)のラクトンに変換すること、あるいは得られる式(I a)または(I b)のラクトンを式(I)の酸またはその塩に変換すること、あるいは得られる式(I)〔式中、部分
は−CH=CH−を表す。〕で示される化合物を式(I)〔式中、部分
を特徴とする方法。
C2−C7アルケニルは、特に、C3−C7アルケニルであり、そして、たとえば、2−プロペニルまたは1−、2−または3−ブテニルである。C3−C5アルケニルが好適である。
C2−C7−アルキニルは、特に、C3−C7アルキニルであり、そして好ましくはプロパルギルである。
C3−C8シクロアルキルは、たとえば、シクロプロピル、シクロブチル、シクロペンチル、シクロヘキシルおよびシクロヘプチルである。シクロペンチルおよびシクロヘキシルが好適である。
C3−C8シクロアルケニルは、特に、C3−C7シクロアルケニルであり、そして好ましくはシクロペンタ−2−エン−イルおよびシクロペンタ−3−エニル、またはシクロヘキサ−2−エン−イルおよびシクロヘキサ−3−エン−イルである。
Mは、Ru、Rh、Ir、好ましくはRuである。
L2は、イソプロピルメチルベンゼン、ベンゼン、ヘキサメチルベンゼン、メシチレンであり、イソプロピルメチルベンゼンが好適である。
R5は、2−または3−または4−ピリジル、4−クロロ−4−フェノキシ−フェニル、4−フェノキシ−フェニル、5−ジ(メ)エチルアミノ−1−ナフチル、5−ニトロ−1−ナフチル、2−、3−、4−ニトロフェニル、4−ビニルフェニル、4−ビフェニリル、9−アントラセニル、2,3または4 ヒドロキシフェニル、トリル、フェナントリル、ベンゾ[1,3]−ジオキソール、ジメチル(ナフタレン−1−イル)−アミン、モノ〜トリストリフルオロメチルフェニル、クリセニル、ペリレニルまたはピレニルまたは2−フェニルエテンである。
R6およびR7は、それぞれ独立して、フェニル、4−メチルフェニルまたは3,5−ジメチルフェニルであり、フェニルが好適である。
R8およびR9は、フェニルまたはシクロヘキシルまたは置換フェニルであり、好ましくはフェニルである。
好適なHalは塩素である。
好適なR15はHである。
L1は上で定義したとおりである。
反応工程(a)において、式(II b)の化合物との式(II a)の化合物の反応は、適当な不活性溶媒、たとえばニトリル、とりわけアセトニトリルまたはプロピオンニトリル、および、たとえば、−78℃から溶媒の沸点までの範囲の温度、好ましくは溶媒の沸点にて行われる。
反応工程(b)は、とりわけ式(II d)のキラルRu(II)触媒および水素ドナーを用いる、不斉移動型水素化法(asymmetric transfer hydrogenation)である。
である。
縮合工程(c)は、縮合系の存在下で、そして適当な不活性溶媒、たとえばエーテル、とりわけテトラヒドロフランまたはtert−ブチル−エチルエーテル中で、たとえば−78℃から溶媒の沸点までの範囲の温度で、好ましくは室温にて行われる。
好適な還元剤は、好ましくはジ−C1−C7アルキル−C1−C7アルコキシ−ボラン、最も好ましくはジエチル−メトキシ−ボランの存在下での、たとえば水素化物、たとえば水素化ホウ素アルカリ金属、とりわけ水素化ホウ素ナトリウムである。
けん化工程(e)は、たとえば式(II h)のエステルを強塩基、たとえばアルカリ金属水酸化物、好ましくはNaOH、またはCa(OH)2で処理し、そして得られる反応混合物を酸性化することにより行われる。
式(I)の化合物の単離工程(f)は、慣用的な単離方法にしたがって、たとえば反応混合物から得られる式(I)の化合物の結晶化または反応混合物のクロマトグラフィーにより行われる。
で示される基であり、部分
は−CH=CH−を表し、そしてR4はC1−C4アルコキシ、とりわけメトキシまたはエトキシまたはtert−ブトキシである式(II c)の化合物がとりわけ好適である。
で示される基であり、部分
[式中、
nは0、1、2、3、4、5、6または7であり;
XはOまたはSであり;
R10はポリスチロール(polystyrol)であり;
R11はシリカゲルであり;
R12は架橋ポリスチロールであり;
R13はポリエチレン−グリコールであり;
R14はC1−C6アルキルであり;そして
mは1、2または3である。]
で示される基である。〕。
〔式中、R5、R8およびR9は上で定義したとおりである。〕
で示される化合物を、[MCl2(p−シメン)]2と慣用的方法で反応させることにより製造される。
は−CH=CH−を表す。〕の化合物の、式(I)〔式中、部分
作業実施例:
ピタバスタチンの出発物質の製造:
(3−エトキシカルボニル−3−オキソプロピル) トリフェニルホスホニウムクロライドの製造:
文献:C.M.Moorhoff; J.C.S. Perkin Trans I, 1987 (1997)にしたがう。
a) エチル 3−オキソ−4−(トリフェニルホスホラニリデン)ブタノエートの製造:
δ=7.56 (m, 6H, オルトH−フェニル), 7.44 (m, 3H, パラH−フェニル), 7.35 (m, 6H, メタH−フェニル), 4.08 (q, 2H, OCH2CH3), 3.72 (d, 1H, H-4), 3.26 (d, 2H, H-2), 1.17 (t, 3H, OCH2CH3)。
保持時間1:16.17分;51.52 %(面積)
保持時間2:18.00分;48.48 %(面積)
13C NMR (100 MHz, CDCl3):172.2, 163.6, 161.1, 160.7, 146.9, 144.4, 138.2, 133.4, 132.0, 131.9, 131.9, 131.8, 129.0, 128.9, 126.5, 126.1, 125.5, 115.5, 115.3, 68.8, 41.1, 16.1, 14.2, 10.4, 10.3。
MS:405.47。
イリド 3−オキソ−4−(トリフェニルホスホラニリデン)ブタノエート(5.0g、12.8mmol)を、アルゴン雰囲気下で、100mlのアセトニトリルに溶かす。激しい撹拌下で、3−(4−フルオロ−フェニル)−1−イソプロピル−1H−インドール−2−カルボアルデヒド(4.2g、10.7mmol)を5回に分けて添加し、次いで、加熱還流する。50時間後、反応液を室温まで冷却する。やや褐色の溶媒を蒸発させ、そして残渣を真空下で乾燥すると、褐色のろう状オイルを得る。ヘキサン:酢酸エチル(4:1 / v:v)を用いるシリカゲルクロマトグラフィーにより、黄色のオイルの(E)−5−[3−(4−フルオロ−フェニル)−1−イソプロピル−1H−インドール−2−イル]−3−オキソ−ペンタ−4−エン酸 エチルエステルを得る。MS:393.46。
(E)−5−[3−(4−フルオロ−フェニル)−1−イソプロピル−1H−インドール−2−イル]−3−オキソ−ペンタ−4−エン酸 エチルエステル(2.0g、5.08mmol)、Ru[(1R,2R)−p−TsNCH(C6H5)CH(C6H5)NH2]Cl(η6−p−シメン)(12.8mg、0.025mmol)およびHCOOH(1.40g、30.5mmol)/NEt3(1.23g、12.2mmol)の混合物の溶液を、DMF(8.0ml)中で50℃にて21時間加熱する。その後、溶液をMTBE(5ml)で抽出し、そしてNaHCO3(4ml)で中和する。NaCl溶液での標準的水性後処理およびMTBEでの抽出および溶媒の除去により粗生成物を得る。溶離液として4:1 ヘキサン−MTBE混合液を用いるシリカゲルクロマトグラフィーにより、(E)−(S)−5−[3−(4−フルオロ−フェニル)−1−イソプロピル−1H−インドール−2−イル]−3−ヒドロキシ−ペンタ−4−エン酸 エチルエステルを得る。
MS:395.48
Claims (7)
- 式
で示される化合物またはその塩、またはそのラクトンの製造法であって、本発明にしたがって、
(a)式(II a)
で示される化合物を、式
R−CH(=O)(II b)
〔式中、Rは環状残基を示す。〕
で示される化合物と反応させること;および
(b)得られる式(II c)
で示される化合物を、式(II d)、(II d')、(II d'')、(II d''')、(II d'''')、(II d''''')、(II d'''''')、および(II d''''''')
MはRu、Rh、Ir、Fe、CoまたはNiであり;
L1は水素であり;
L2はアリールまたはアリール−脂肪族残基を表し;
Halはハロゲンであり;
R5は脂肪族、環状脂肪族、環状脂肪族−脂肪族、アリールまたはアリール−脂肪族残基であり、これらは、それぞれの場合において、ポリマーと結合していてもよく;
R6およびR7は、それぞれ独立して、脂肪族、環状脂肪族、環状脂肪族−脂肪族、アリールまたはアリール−脂肪族残基であり;
R8およびR9は、ぞれぞれ、フェニルであるか、またはR8およびR9はそれらが結合している炭素原子と一体となって、シクロヘキサンまたはシクロペンタン環を形成し;そして
R15はH、ハロゲン、アミノ、ニトロまたはC1−C7アルコキシであり;
式(IId)、(IId')、(IId'')、(IId''')、(IId'''')、(IId''''')、(IId'''''')または(IID''''''')で示される化合物の任意の芳香族残基は非置換であるかまたは置換されており;
式(IId'')、(IId''')、(IId'''')、(IId''''')、(IId'''''')または(IID''''''')の化合物に関して、また、(R)−または(S)−BINAPとの組合せも可能である。〕
で示される化合物からなる群から選択される還元剤の存在下で還元すること;および
(c)得られる式(II e)
で示される化合物を、式(II f)
で示される化合物と縮合すること、および
(d)得られる式(II g)
で示される化合物を還元すること、および
(e)得られる式(II h)
で示される化合物を加水分解すること、および
(f)得られる式(I)の化合物またはその塩を単離すること;
および、所望により、得られる式(I)の遊離酸をその塩または、それぞれ、式(I a)もしくは(I b)のラクトンに変換すること、あるいは得られる式(I a)または(I b)のラクトンを式(I)の酸またはその塩に変換すること、あるいは得られる式(I)〔式中、部分
を特徴とする方法。 - 式(II a)、(II c)、(II e)、(II g)および(II h)〔式中、R4またはR16は、それぞれ、C1−C4アルキル、とりわけメチルまたはエチルまたは最も好ましくはtert−ブチルを表す。〕の化合物が使用される、請求項1に記載の方法。
- 式(II e)
で示される化合物の製造方法であって、
得られる式(II c)
で示される化合物を、式
nは0、1、2、3、4、5、6または7であり;
XはOまたはSであり;
R10はポリスチロールであり;
R11はシリカゲルであり;
R12は架橋ポリスチロールであり;
R13はポリエチレン−グリコールであり;
R14はC1−C6アルキルであり;そして
mは1、2または3である。]
で示される基である。〕
で示される還元剤の存在下で還元することを特徴とする方法。 - 式(II d)〔式中、L1は水素であり、そしてL2はフェニル、あるいは1、2、3、4または5個のアルキル残基、とりわけイソプロピルにより1回置換されたフェニル、たとえば4−イソプロピル−フェニルを表し、そしてR5は2−または3−または4−ピリジル、4−クロロ−4−フェノキシ−フェニル、4−フェノキシ−フェニル、5−ジ(メ)エチルアミノ−1−ナフチル、5−ニトロ−1−ナフチル、2−、3−、4−ニトロフェニル、4−ビニルフェニル、4−ビフェニリル、9−アントラセニル、2,3−、4−ヒドロキシフェニル、トリル、フェナントリル、ベンゾ[1,3]−ジオキソール、ジメチル(ナフタレン−1−イル)−アミン、モノ〜トリストリフルオロメチルフェニル、クリセニル、ペリレニルおよびピレニルあるいは2−フェニルエテンからなる群から選択される残基を表す。〕で示される化合物。
- 式(II d'')および(IId''')〔式中、Halは、それぞれの場合において、塩素であり;R6およびR7は、それぞれの場合において、フェニル、または1もしくはそれ以上のC1−C7アルキル、とりわけ3,5−ジメチルフェニルにより置換されたフェニルを表す。〕で示される化合物。
- 式(II d'''')および(IId''''')〔式中、Halは、それぞれの場合において、塩素であり;R6およびR7は、それぞれの場合において、フェニル、または1もしくはそれ以上のC1−C7アルキルにより置換されたフェニルを表し、とりわけ3,5−ジメチルフェニルを表す。〕で示される化合物。
- 式(II d''''')および(IId'''''')〔式中、Halは、それぞれの場合において、塩素であり;R6およびR7は、それぞれの場合において、フェニル、または1もしくはそれ以上のC1−C7アルキルにより置換されたフェニルを表し、とりわけ3,5−ジメチルフェニルを表す。〕で示される化合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0204129.1A GB0204129D0 (en) | 2002-02-21 | 2002-02-21 | Process for the manufacture of organic compounds |
PCT/EP2003/001738 WO2003070717A1 (en) | 2002-02-21 | 2003-02-20 | Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2005520818A true JP2005520818A (ja) | 2005-07-14 |
Family
ID=9931523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003569624A Pending JP2005520818A (ja) | 2002-02-21 | 2003-02-20 | Hmg−coaレダクターゼ阻害性メバロン酸誘導体の製造方法 |
Country Status (18)
Country | Link |
---|---|
US (3) | US7208623B2 (ja) |
EP (1) | EP1478640A1 (ja) |
JP (1) | JP2005520818A (ja) |
KR (1) | KR100978970B1 (ja) |
CN (1) | CN1318412C (ja) |
AU (1) | AU2003218994B2 (ja) |
BR (1) | BR0307801A (ja) |
CA (1) | CA2473075A1 (ja) |
EC (1) | ECSP045234A (ja) |
GB (1) | GB0204129D0 (ja) |
IL (1) | IL163279A (ja) |
MX (1) | MXPA04008110A (ja) |
NO (1) | NO20043919L (ja) |
NZ (1) | NZ534394A (ja) |
PL (1) | PL370596A1 (ja) |
RU (1) | RU2335500C2 (ja) |
WO (1) | WO2003070717A1 (ja) |
ZA (1) | ZA200405436B (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0204129D0 (en) | 2002-02-21 | 2002-04-10 | Novartis Ag | Process for the manufacture of organic compounds |
CA2785954A1 (en) | 2003-02-12 | 2004-08-26 | Nissan Chemical Industries, Ltd. | Crystalline forms of pitavastatin calcium |
GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
US20070179166A1 (en) * | 2003-12-24 | 2007-08-02 | Valerie Niddam-Hildesheim | Process for preparation of statins with high syn to anti ratio |
US7851624B2 (en) * | 2003-12-24 | 2010-12-14 | Teva Pharamaceutical Industries Ltd. | Triol form of rosuvastatin and synthesis of rosuvastatin |
EP1634870A1 (en) * | 2004-08-27 | 2006-03-15 | Zhejiang Hisun Pharmaceutical Co. Ltd. | Process and intermediates for the selective synthesis of Fluvastatin |
WO2006035286A2 (en) * | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | Process for preparating enantiomerically pure fluvastatin sodium and a novel polymorphic form thereof |
WO2007017117A1 (en) * | 2005-07-28 | 2007-02-15 | Lek Pharmaceuticals D.D. | Process for the synthesis of rosuvastatin calcium |
US8455640B2 (en) | 2006-05-03 | 2013-06-04 | Msn Laboratories Limited | Process for statins and its pharmaceutically acceptable salts thereof |
US8404841B2 (en) | 2006-10-09 | 2013-03-26 | Msn Laboratories Limited | Process for the preparation of statins and their pharmaceutically acceptable salts thereof |
EP2079712A2 (en) * | 2006-10-31 | 2009-07-22 | Aurobindo Pharma Limited | An improved process for preparing rosuvastatin calcium |
EP2125754B1 (en) * | 2007-02-08 | 2012-04-11 | Aurobindo Pharma Limited | Process for preparation of rosuvastatin calcium |
EP2032587A2 (en) * | 2007-04-18 | 2009-03-11 | Teva Pharmaceutical Industries Ltd. | Rosuvastatin intermediates and process for the preparation of rosuvastatin |
US7884226B2 (en) * | 2007-07-12 | 2011-02-08 | Teva Pharmaceutical Industries, Ltd. | Purification of rosuvatatin intermediate by thin film evaporation and chemical method |
KR101063146B1 (ko) * | 2008-11-10 | 2011-09-07 | 미래파인켐 주식회사 | 피타바스타틴 중간체의 제조방법 및 이를 이용한 피타바스타틴 헤미 칼슘염의 제조방법 |
EP2387561A4 (en) | 2009-01-19 | 2012-07-25 | Msn Lab Ltd | IMPROVED PROCESS FOR THE PREPARATION OF HIGH-PURITY (3R, 5S) -7-β-CYCLOPROPYL-4- (4-FLUOROPHENYL) QUINOLIN-3-YL-3,5-DIHYDROXY-6 (E) -HEPTENOIC ACID, INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS |
WO2011086584A2 (en) | 2010-01-18 | 2011-07-21 | Msn Laboratories Limited | Improved process for the preparation of amide intermediates and their use thereof |
EP2638013A4 (en) * | 2010-11-12 | 2014-03-26 | Hetero Research Foundation | NEW POLYMORPHS OF CALCIUM PIVASTATIN |
FR2970178B1 (fr) | 2011-01-07 | 2014-06-20 | Liliane Therese Jacquot | Promedicaments pour une delivrance specifique au niveau du foie et une meilleure tolerance |
CN103058925B (zh) * | 2011-11-02 | 2015-09-02 | 石药集团中奇制药技术(石家庄)有限公司 | 一种匹伐他汀钙的制备方法 |
TWI516520B (zh) | 2014-10-31 | 2016-01-11 | 財團法人工業技術研究院 | 波長轉換聚合物、其製法及包含其之波長轉換裝置 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997020789A1 (fr) * | 1995-12-06 | 1997-06-12 | Japan Science And Technology Corporation | Procede de preparation de composes optiquement actifs |
JPH10236986A (ja) * | 1997-02-21 | 1998-09-08 | Kagaku Gijutsu Shinko Jigyodan | 光学活性アルコール類の製造方法 |
JPH11236345A (ja) * | 1997-11-06 | 1999-08-31 | F Hoffmann La Roche Ag | トランス−(r,r)−アクチノール |
JPH11322649A (ja) * | 1998-03-16 | 1999-11-24 | Mitsubishi Chemical Corp | 光学活性アルコールの製造方法 |
JPH11335385A (ja) * | 1998-05-20 | 1999-12-07 | Takasago Internatl Corp | 遷移金属錯体および該錯体を用いた光学活性アルコールの製造方法 |
JP2000212110A (ja) * | 1999-01-27 | 2000-08-02 | Mitsubishi Chemicals Corp | 光学活性α―アルキルベンジルアルコ―ル類の製造方法 |
JP2000256234A (ja) * | 1999-03-03 | 2000-09-19 | Mitsubishi Chemicals Corp | 光学活性1,2−ジオール類の製造方法 |
JP2000327659A (ja) * | 1999-03-15 | 2000-11-28 | Mitsubishi Chemicals Corp | 光学活性ピリジルアルコール類の製造方法 |
JP2001104795A (ja) * | 1999-10-13 | 2001-04-17 | Mitsubishi Chemicals Corp | ルテニウム触媒組成物 |
JP2001261689A (ja) * | 2000-03-14 | 2001-09-26 | Takasago Internatl Corp | 光学活性ルテニウムホスフィン錯体の製造方法及び該錯体を用いた光学活性アルコールの製造方法 |
JP2001270865A (ja) * | 2000-03-22 | 2001-10-02 | F Hoffmann La Roche Ag | エタンスルホニルピペリジン誘導体の製造方法 |
WO2001092223A1 (en) * | 2000-05-26 | 2001-12-06 | Ciba Specialty Chemicals Holding Inc. | Process for the preparation of indole derivatives and intermediates of the process |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4851427A (en) | 1985-10-25 | 1989-07-25 | Sandoz Pharm. Corp. | Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use |
CA1336714C (en) | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
SG44830A1 (en) | 1992-07-02 | 1997-12-19 | Hoechst Ag | Process for preparing tert-butyl 93R,5S) -6 Hydroxy-3,5-O-Isopropylidene-3, 5-Dihydroxyhexanoate |
EP0718265B1 (en) | 1994-12-07 | 2000-08-23 | Nkk Corporation | Method for producing an alcohol |
US6211412B1 (en) * | 1999-03-29 | 2001-04-03 | The University Of Kansas | Synthesis of epothilones |
US6603015B2 (en) * | 1999-03-29 | 2003-08-05 | University Of Kansas | Synthesis of epothilones |
WO2002008169A1 (en) * | 2000-07-24 | 2002-01-31 | Chirotech Technology Limited | Ruthenium complexes and their use in asymmetric hydrogenation |
GB0204129D0 (en) | 2002-02-21 | 2002-04-10 | Novartis Ag | Process for the manufacture of organic compounds |
-
2002
- 2002-02-21 GB GBGB0204129.1A patent/GB0204129D0/en not_active Ceased
-
2003
- 2003-02-20 BR BR0307801-9A patent/BR0307801A/pt not_active IP Right Cessation
- 2003-02-20 JP JP2003569624A patent/JP2005520818A/ja active Pending
- 2003-02-20 KR KR1020047013033A patent/KR100978970B1/ko not_active IP Right Cessation
- 2003-02-20 RU RU2004128256/04A patent/RU2335500C2/ru not_active IP Right Cessation
- 2003-02-20 MX MXPA04008110A patent/MXPA04008110A/es active IP Right Grant
- 2003-02-20 CN CNB038042886A patent/CN1318412C/zh not_active Expired - Fee Related
- 2003-02-20 PL PL03370596A patent/PL370596A1/xx not_active Application Discontinuation
- 2003-02-20 NZ NZ534394A patent/NZ534394A/en not_active IP Right Cessation
- 2003-02-20 CA CA002473075A patent/CA2473075A1/en not_active Abandoned
- 2003-02-20 AU AU2003218994A patent/AU2003218994B2/en not_active Ceased
- 2003-02-20 EP EP03714750A patent/EP1478640A1/en not_active Withdrawn
- 2003-02-20 US US10/504,655 patent/US7208623B2/en not_active Expired - Fee Related
- 2003-02-20 WO PCT/EP2003/001738 patent/WO2003070717A1/en active IP Right Grant
-
2004
- 2004-07-08 ZA ZA200405436A patent/ZA200405436B/en unknown
- 2004-07-29 IL IL163279A patent/IL163279A/en not_active IP Right Cessation
- 2004-08-16 EC EC2004005234A patent/ECSP045234A/es unknown
- 2004-09-20 NO NO20043919A patent/NO20043919L/no not_active Application Discontinuation
-
2007
- 2007-03-09 US US11/684,134 patent/US20070155970A1/en not_active Abandoned
-
2008
- 2008-07-23 US US12/220,259 patent/US20080312462A1/en not_active Abandoned
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997020789A1 (fr) * | 1995-12-06 | 1997-06-12 | Japan Science And Technology Corporation | Procede de preparation de composes optiquement actifs |
JPH10236986A (ja) * | 1997-02-21 | 1998-09-08 | Kagaku Gijutsu Shinko Jigyodan | 光学活性アルコール類の製造方法 |
JPH11236345A (ja) * | 1997-11-06 | 1999-08-31 | F Hoffmann La Roche Ag | トランス−(r,r)−アクチノール |
JPH11322649A (ja) * | 1998-03-16 | 1999-11-24 | Mitsubishi Chemical Corp | 光学活性アルコールの製造方法 |
JPH11335385A (ja) * | 1998-05-20 | 1999-12-07 | Takasago Internatl Corp | 遷移金属錯体および該錯体を用いた光学活性アルコールの製造方法 |
JP2000212110A (ja) * | 1999-01-27 | 2000-08-02 | Mitsubishi Chemicals Corp | 光学活性α―アルキルベンジルアルコ―ル類の製造方法 |
JP2000256234A (ja) * | 1999-03-03 | 2000-09-19 | Mitsubishi Chemicals Corp | 光学活性1,2−ジオール類の製造方法 |
JP2000327659A (ja) * | 1999-03-15 | 2000-11-28 | Mitsubishi Chemicals Corp | 光学活性ピリジルアルコール類の製造方法 |
JP2001104795A (ja) * | 1999-10-13 | 2001-04-17 | Mitsubishi Chemicals Corp | ルテニウム触媒組成物 |
JP2001261689A (ja) * | 2000-03-14 | 2001-09-26 | Takasago Internatl Corp | 光学活性ルテニウムホスフィン錯体の製造方法及び該錯体を用いた光学活性アルコールの製造方法 |
JP2001270865A (ja) * | 2000-03-22 | 2001-10-02 | F Hoffmann La Roche Ag | エタンスルホニルピペリジン誘導体の製造方法 |
WO2001092223A1 (en) * | 2000-05-26 | 2001-12-06 | Ciba Specialty Chemicals Holding Inc. | Process for the preparation of indole derivatives and intermediates of the process |
Also Published As
Publication number | Publication date |
---|---|
CN1636004A (zh) | 2005-07-06 |
US20070155970A1 (en) | 2007-07-05 |
AU2003218994B2 (en) | 2007-08-09 |
GB0204129D0 (en) | 2002-04-10 |
NO20043919L (no) | 2004-09-20 |
RU2004128256A (ru) | 2005-06-27 |
KR20040111360A (ko) | 2004-12-31 |
ECSP045234A (es) | 2004-09-28 |
ZA200405436B (en) | 2005-06-17 |
RU2335500C2 (ru) | 2008-10-10 |
US20080312462A1 (en) | 2008-12-18 |
US20050159480A1 (en) | 2005-07-21 |
NZ534394A (en) | 2006-10-27 |
AU2003218994A1 (en) | 2003-09-09 |
IL163279A (en) | 2010-06-30 |
CA2473075A1 (en) | 2003-08-23 |
BR0307801A (pt) | 2004-12-21 |
WO2003070717A1 (en) | 2003-08-28 |
EP1478640A1 (en) | 2004-11-24 |
PL370596A1 (en) | 2005-05-30 |
KR100978970B1 (ko) | 2010-08-30 |
US7208623B2 (en) | 2007-04-24 |
MXPA04008110A (es) | 2004-11-26 |
CN1318412C (zh) | 2007-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080312462A1 (en) | Process for the manufacture of HMG-CoA reductase inhibitory mevalonic acid derivatives | |
EP1341785B1 (en) | Hydrolysis of r(r*,r*)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- [(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide | |
CN108546238B (zh) | α-酮酰胺类化合物的不对称氢化方法 | |
AU2002232891A1 (en) | Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide | |
CN107722068A (zh) | 三齿氮膦配体与其配合物、及其在酮的不对称催化氢化中的应用 | |
US6909003B2 (en) | Process for the manufacture of organic compounds | |
KR20040081161A (ko) | HMG-CoA 환원효소 억제제의 제조 방법 | |
JPH10504845A (ja) | (+)−コンパクチンおよび(+)−メビノリンの類似体であるβ−ヒドロキシ−δ−ラクトン基を含有する化合物の調製方法 | |
JPWO2017057642A1 (ja) | 光学活性な2−(2−フルオロビフェニル−4−イル)プロパン酸の製造法 | |
JP2001526111A (ja) | モリブデン、タングステンまたはクロムを有するキラル配位子をベースとする触媒組成物およびアリル性基質の不斉アルキル化の方法 | |
JP4050294B2 (ja) | 光学活性コバルト(ii)錯体 | |
JPH0665226A (ja) | (3r,5s)−3,5,6−トリヒドロキシヘキサン酸誘導体及びその製造方法 | |
JP3976357B2 (ja) | 光学活性アルコールの製造方法 | |
JP5329462B2 (ja) | 光学活性ジカルボン酸誘導体 | |
EP1070042A2 (en) | Process for the preparation of hpb esters | |
KR100619117B1 (ko) | 시스-시클로프로판-감마-부티로락톤 화합물 및 그의제조방법 | |
KR0149634B1 (ko) | 3,5-디하이드록시헵트-6-인산의 7-치환된 유도체로부터 제조된 락톤,이의 제조방법 및 이를 포함하는 약제학적 생성물 | |
WO2007004543A1 (ja) | 2-ピリドン誘導体を有効成分とする医薬組成物 | |
JPH10158289A (ja) | 光学活性フェロセニルホスフィン誘導体および光学活性5,9−メタノシクロオクタ[b]ピリジン誘導体の製造方法 | |
JPH0873432A (ja) | 光学活性な7−置換ピリジル−3,5−ジヒドロキシ−ヘプト−6−エン酸エステル誘導体の製法 | |
JPH0971592A (ja) | 光学活性モノホスフィノカルボン酸誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060215 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091006 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091225 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100112 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100208 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100216 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100308 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100713 |